Prostate Cancer
Conditions
Keywords
Prostate Cancer, PC, SNP, Oncology, Genetics, Pharmacogenomics, CYP
Brief summary
The usual approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet, it will try to look for the relationship between the Abiraterone therapeutic efficacy and the CYP17 SNP Genotyping, and the relationship between the Abiraterone therapeutic safety and the SULT2A1 SNP Genotyping, based on Oxford precisely sequencing drug targets' genes. The study approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on China Import - abiraterone acetate tablet plus prednisone tablet plus BICALUTAMIDE tablet, it will try to look for the relationship between the Abiraterone therapeutic efficacy and the CYP17 SNP Genotyping, and the relationship between the Abiraterone therapeutic safety and the SULT2A1 SNP Genotyping, based on Oxford precisely sequencing drug targets' genes.
Detailed description
1. Detect drug target whole gene precision sequence of everyone patient for all 600 recruited double blind prostate cancer patients. 2. Mutually compare everyone patient drug target whole gene precision sequence for a total of 600 recruited double blind prostate cancer patients. 3. Calculate drug target gene SNPs in all 600 recruited double blind prostate cancer patients. 4. Correlate everyone patient drug target gene SNP to everyone patient drug efficacy. 5. Correlate everyone patient drug target gene SNP to everyone patient drug safety. 6. Mutually compare the usual approach group SNPs (300 double blind random group separated prostate cancer patients) with the study approach group SNPs (300 double blind random group separated prostate cancer patients). 7. Confirm the relationship between drug target gene SNPs and drug efficacy. 8. Confirm the relationship between drug target gene SNPs and drug safety.
Interventions
DRUGAbiraterone - Usual
* Oral * Abiraterone Combined Chemotherapy
DRUGAbiraterone - Study
* Oral * Abiraterone Combined Chemotherapy
Sponsors
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
No-placebo and random and double blind
Intervention model description
* The usual approach group * The study approach group
Eligibility
Sex/Gender
MALE
Age
22 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Select 600 localized Prostate Cancer Patients without prostate resection * Dosage Duration at least 90 days * The usual approach group - Recruit 300 double blind random group separated prostate cancer patients currently used the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet, like as the usual approach group. * The study approach group - Recruit 300 double blind random group separated prostate cancer patients currently used the Combined Chemotherapy on China Import - abiraterone acetate tablet plus prednisone tablet plus BICALUTAMIDE tablet, like as the study approach group. Inclusion Criteria: 1. Clinical diagnosis of Prostate Cancer (PC) 2. Cancer in the prostate only 3. Prior therapy without orchiectomy 4. Prior therapy without prostate resection 5. Prior different chemotherapy must-need stop 6. Have no other cancer at the same time 7. Sign an informed consent form 8. Receive blood-drawing
Exclusion criteria
1. Treatment with other anti-cancer therapies and the therapies cannot be stopped currently 2. The patients with other serious intercurrent illness or infectious diseases 3. Have more than one different kind of cancer at the same time 4. Serious Allergy to Drugs 5. Serious Bleed Tendency 6. Serious Risks or Serious Adverse Events of the drug product label 7. Serious Risks or Serious Adverse Events of NCI Table of Side Effects 8. The prohibition of drug products 9. Have no therapeutic effects 10. Follow up to the most current label and plan for safety monitoring
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure and Report Abiraterone Drug Targets' SNP Genotypes which are effectiveness-associated, and which are risk-associated. | Up to 12 weeks | * Recruit 300 double blind random group separated PC patients currently using the Combined Chemotherapy on ZYTIGA - Abiraterone tablet plus Prednisone tablet plus BICALUTAMIDE tablet to be the usual approach group. * Recruit 300 double blind random group separated PC patients currently using the Combined Chemotherapy on China Import - Abiraterone tablet plus Prednisone tablet plus BICALUTAMIDE tablet to be the study approach group. * Measure above every PC patient specific Abiraterone drug target (CYP17) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. * Report every PC patient specific CYP17 SNP genotype in whole genome DNA sequence. * Measure above every PC patient specific Abiraterone drug target (SULT2A1) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. * Report every PC patient specific SULT2A1 SNP genotype in whole genome DNA sequence. |
Countries
United States
Contacts
STUDY_CHAIRHAN XU, MD/PhD/FAPCR
Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701
STUDY_DIRECTORHAN XU, MD/PhD/FAPCR
Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701
PRINCIPAL_INVESTIGATORHAN XU, MD/PhD/FAPCR
Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701
Outcome results
None listed